LENVIMA
PeakNDAORALCAPSULEPriority Review
Approved
Feb 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
3
Data completeness
7/8 — Comprehensive
Priority Review
LENVIMA by Eisai is (vegf) receptors vegfr1 (flt1), vegfr2 (kdr), and vegfr3 (flt4). Approved for metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (dtc) and 5 more indications. First approved in 2015.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LENVIMA (lenvatinib) is an oral receptor tyrosine kinase inhibitor approved in 2015 for multiple cancer indications. It works by blocking multiple kinase pathways to inhibit tumor growth and angiogenesis. The drug is administered as an oral capsule and represents a key option in the kinase inhibitor class.
$779MPart D
PeakStable
12.0 years to LOEPeak lifecycle stage with $779M in Part D spending indicates a mature, established commercial infrastructure requiring defensive market share protection and optimization.
Mechanism of Action
(VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2,…
Indications (7)
Worked on LENVIMA at Eisai? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.